Liminatus Pharma awaits Nasdaq ruling after saying equity tops $2.5 million threshold
LIMN•Nasdaq compliance update after InnocsAI merger
Liminatus Pharma is awaiting a Nasdaq compliance determination on its stockholders’ equity requirement following its merger with InnocsAI.
The company believes stockholders’ equity now exceeds $2.5 million, a key threshold for continued Nasdaq listing.
Nasdaq will keep monitoring the equity level; a shortfall at the next periodic report could trigger a future delisting risk.
